Saudi Central Bank Acquires 41,091 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Saudi Central Bank increased its Gilead Sciences stake by 89.7% in the second quarter, acquiring 41,091 shares and bringing its holdings to 86,886 shares valued at approximately $11.0 billion. Institutional investors collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.80 billion, ahead of estimates, with revenue up 10.6% year over year. The company also declared a quarterly dividend of $0.82, or $3.28 annualized, representing a 2.2% yield.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $158.04, while new HIV and oncology approvals support growth prospects. However, investors face risks from insider selling, dependence on the HIV franchise and future patent expirations.

Saudi Central Bank lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 89.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 86,886 shares of the biopharmaceutical company's stock after buying an additional 41,091 shares during the quarter. Saudi Central Bank's holdings in Gilead Sciences were worth $10,977,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Gilead Sciences in the 2nd quarter valued at about $15,393,785,000. Norges Bank acquired a new position in Gilead Sciences during the 4th quarter worth approximately $2,617,152,000. Legal & General Group Plc bought a new position in Gilead Sciences in the second quarter worth approximately $1,316,606,000. Deutsche Bank AG bought a new position in Gilead Sciences in the second quarter worth approximately $918,387,000. Finally, Boston Partners acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $517,808,000. Institutional investors own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the transaction, the chief financial officer directly owned 165,646 shares of the company's stock, valued at approximately $22,918,780.56. The trade was a 1.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 105,000 shares of company stock worth $14,495,820. Company insiders own 0.30% of the company's stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article
• Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates
• Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article
• Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article
• Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing
• Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a research report on Wednesday, August 5th. Wall Street Zen lowered shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Saturday. Truist Financial lowered their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a report on Tuesday, July 7th. Finally, Zacks Research raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $158.04.

Gilead Sciences Trading Down 0.2%

Shares of GILD stock opened at $150.99 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a market capitalization of $187.22 billion, a price-to-earnings ratio of -56.55 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a 50-day simple moving average of $136.67 and a two-hundred day simple moving average of $136.52.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences's payout ratio is currently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source